Eris Lifesciences Limited (BOM:540596)

Market Cap	242.46B
Revenue (ttm)	28.79B
Net Income (ttm)	3.52B
Shares Out	n/a
EPS (ttm)	25.81
PE Ratio	68.91
Forward PE	44.39
Dividend	7.35 (0.45%)
Ex-Dividend Date	Feb 13, 2025

Volume	14,228
Average Volume	15,872
Open	1,630.15
Previous Close	1,618.95
Day's Range	1,623.85 - 1,696.85
52-Week Range	988.95 - 1,909.55
Beta	n/a
RSI	54.78
Earnings Date	Aug 4, 2025

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measureme...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 3,620
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540596

Financial Performance

In 2024, Eris Lifesciences's revenue was 28.79 billion, an increase of 44.59% compared to the previous year's 19.91 billion. Earnings were 3.52 billion, a decrease of -10.24%.